human | Q5 |
P496 | ORCID iD | 0000-0002-9626-5083 |
P734 | family name | Geier | Q21509304 |
Geier | Q21509304 | ||
Geier | Q21509304 | ||
P735 | given name | Andreas | Q4926263 |
Andreas | Q4926263 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | male | Q6581097 |
Q90697684 | A 2-step fast-track elastometry service for advanced workup of nonalcoholic fatty liver disease (NAFLD) patients - single-center real-world experience of outpatient clinical practice |
Q53298107 | A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. |
Q45140568 | Adaptation of iron transport and metabolism to acute high-altitude hypoxia in mountaineers |
Q38737633 | Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease |
Q61218108 | Combined effect of 25-OH vitamin D plasma levels and genetic Vitamin DReceptor (NR 1I1) variants on fibrosis progression rate in HCV patients |
Q87889291 | Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers |
Q81424742 | Cytokine-independent repression of rodent Ntcp in obstructive cholestasis |
Q114615576 | Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis |
Q42269830 | Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients |
Q38748157 | Emerging therapies for NASH - the future is now. |
Q90697300 | Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis |
Q36482742 | Host genetic variants in the pathogenesis of hepatitis C. |
Q44487750 | Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection |
Q94588841 | Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Non-carriers |
Q36606886 | Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. |
Q92521100 | Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness |
Q113859042 | NAFLD patients scheduled for bariatric surgery present with a milder disease phenotype as compared to not morbidly obese NAFLD patients: analysis of a large real-world cohort |
Q64121032 | Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective |
Q90710997 | Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts? |
Q45043485 | Reply to: "estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?". |
Q46588775 | Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver |
Q44749286 | Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. |
Q34251524 | The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients |
Search more.